Amryt Pharma Share Discussion Threads

[bioking] 05/2/2019 12:55

thats what most guys called about fum now look where its now which i bought at 7p .Best time to invest in biotechs is when theyre close to MAJOR milestones and the Phase 3 readout for their potential blockbuster in second half is a MEGA milestone . And Management said there will be more Product acquisitions in near term so that will be another share price booster and of course the lojuxta sales .

Just look at Amicus which has a huge valaution of $2+ billion with only 1 drug approved that company burning around $300 million a year and has over $300 million debt . Our Company has a laughable valuation of 44 million and has way better pipeline than Amicus . The problem with AMYT is that this stock is almost unknown and has only a LSE listing if this stock would also trade on Nasdaq then you can be sure that AMYT would be north of £2 right now . Lets contact IR and asking them about a US listing .

[bioking] 05/2/2019 12:26

hey guys come over to the interactive investor board started a thread there .thanks
hxxps://www.ii.co.uk/discussion/tags/lse:amyt

[bazworth] 05/2/2019 12:16

Thank you, just realised the MC shown in the ADVFN header is wrong! Well done!

[bioking] 05/2/2019 12:11

from my own math O/S 274800000 x share price 0.16 = market cap of 43.96 million

[bazworth] 05/2/2019 11:45

£44M, where do you get that from?

[bioking] 05/2/2019 11:36

added another 20k shares today i have a good feeling that a rally like it happen on my other bio favorite FUM will start soon .This stock is definitely MASSIVE underpriced should be at minimum 80-100p also the priority review voucher is worth more than $80 million . AMYT is also a very attractive takeover target because of its very low valuation of 44 million .

[bazworth] 05/2/2019 09:39

Can't we just have a little fun!?

[bazworth] 05/2/2019 09:07

We would appear to be in the starting blocks for our long awaited WHOOOOOOOOSH!

Cheers

Baz

[bioking] 04/2/2019 10:11

amyt and fum are my absolute top favorites for 2019 and im already up more than 100% with my fum and amyt will follow this track too.


EB is a devastating, rare genetic skin disorder that can cause skin to blister and tear from the slightest friction or trauma and can, in some cases, cause blistering and erosion of the epithelial lining of internal organs. EB is chronic, potentially disfiguring and life limiting. There are approximately 500,000 people living with EB worldwide and there are currently no approved treatments.1 It is estimated that the annual market potential for AP101 is more than €1 billion.

[volsung] 04/2/2019 10:00

Added another tranche this morning. Hopefully some nice upward force soon

[bioking] 04/2/2019 09:54

hey guys startd a position here last week after doing my dd and will continue to buy more step by step .the potential here is huge especially if phase 3 outcome of AP101 is positive then amryt has 10 bagger potential easily .There is NO approved drug to date for EB a $1.5+ BILLION Market alone the priority review voucher is worth more than the entire valuation of amryt .LOVE IT

[papillon] 04/2/2019 08:47

Another 4 trades. All sells. Volume so far today 128,546. At least there is some interest in AMYT!

[papillon] 04/2/2019 08:36

Many thanks, Bermudashorts. Bit of interest so far this morning. 5 trades. 4 buys, I sell of 25,000. 61,500 shares traded.

[bermudashorts] 03/2/2019 23:25

Yes, my strategy is to take a long position on a handful of bio stocks - have had some great successes and spectacular failures but overall it's a strategy that works for me.

[papillon] 03/2/2019 22:52

Hi Bermudashorts. From your recent posting history I notice you post on AGL, SCLP & MTFB. If you don't mind me asking, do you hold them?

The AGL & MTFB charts are bullish. Not so SCLP. It's very bearish.

[bazworth] 02/2/2019 16:07

Thanks for posting that! There is hope!

[bermudashorts] 02/2/2019 15:48

Not sure whether this has already been posted but link below is to research from the University of Palermo reviewing the use of Lojuxta in HoFH.

Concluision - 'Lomitapide represents an innovative and efficacious drug for the treatment of HoFH.'

[bermudashorts] 30/1/2019 20:34

Amryt are sponsoring Heart UK's Medical & Scientific Conference in July. Other sponsors are Amgen and Sanofi.

[papillon] 30/1/2019 16:45

Does the AMYT share price do anything lately apart from go horizontally sideways? It appears not! However I suspect it will move dramatically on the next RNS, be it up, or down!

[papillon] 29/1/2019 21:21

Well the share price has flatlined for the last 9 days. Yawn!